RNAZ (TransCode Therapeutics, Inc. Common Stock) Stock Analysis - SEC Filings

TransCode Therapeutics, Inc. Common Stock (RNAZ) is a publicly traded Healthcare sector company. As of May 21, 2026, RNAZ trades at $6.35 with a market cap of $5.66M and a P/E ratio of -0.12. RNAZ moved +0.00% today. Year to date, RNAZ is -17.43%; over the trailing twelve months it is -25.12%. Its 52-week range spans $5.56 to $739.20. Rallies surfaces RNAZ's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Where can I find RNAZ SEC filings?

Rallies organizes RNAZ SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.

RNAZ Key Metrics

Key financial metrics for RNAZ
MetricValue
Price$6.35
Market Cap$5.66M
P/E Ratio-0.12
EPS$-52.59
Dividend Yield0.00%
52-Week High$739.20
52-Week Low$5.56
Volume0
Avg Volume0
Revenue (TTM)$0
Net Income$-34.66M
Gross Margin0.00%

Latest RNAZ News

Recent RNAZ Insider Trades

  • Fitzgerald Thomas A bought 49.35K (~$25.17K) on Sep 28, 2023.
  • Dudley Robert Michael bought 98.00K (~$49.98K) on Sep 28, 2023.
  • Dudley Robert Michael bought 12.00K (~$31.82K) on Jun 21, 2023.

RNAZ Analyst Consensus

RNAZ analyst coverage data. Average price target: $0.00.

Common questions about RNAZ

Where can I find RNAZ SEC filings?
Rallies organizes RNAZ SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
Does Rallies show RNAZ 10-K and 10-Q filings?
Rallies organizes RNAZ SEC filing research, including 10-K reports, 10-Q reports, company disclosures, and filing-driven context when available.
Is RNAZ research on Rallies investment advice?
No. Rallies provides research, data, and educational context for RNAZ. It does not provide personalized investment advice.
RNAZ

RNAZ